Sonoma Pharmaceuticals In... (SNOA)
Sonoma Pharmaceuticals Statistics
Share Statistics
Sonoma Pharmaceuticals has 1.62M shares outstanding. The number of shares has increased by -91.5% in one year.
Shares Outstanding | 1.62M |
Shares Change (YoY) | -91.5% |
Shares Change (QoQ) | 20.65% |
Owned by Institutions (%) | 2.79% |
Shares Floating | 1.59M |
Failed to Deliver (FTD) Shares | 3.24K |
FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 62.63K, so 3.88% of the outstanding shares have been sold short.
Short Interest | 62.63K |
Short % of Shares Out | 3.88% |
Short % of Float | 3.93% |
Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.58 and the forward PE ratio is -2.16. Sonoma Pharmaceuticals's PEG ratio is 0.01.
PE Ratio | -0.58 |
Forward PE | -2.16 |
PS Ratio | 0.22 |
Forward PS | 0.3 |
PB Ratio | 0.45 |
P/FCF Ratio | -1.15 |
PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Sonoma Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.37, with a Debt / Equity ratio of 0.1.
Current Ratio | 3.37 |
Quick Ratio | 2.64 |
Debt / Equity | 0.1 |
Debt / EBITDA | -0.13 |
Debt / FCF | -0.25 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $1.27M |
Profits Per Employee | $-483.5K |
Employee Count | 10 |
Asset Turnover | 0.86 |
Inventory Turnover | 2.94 |
Taxes
Income Tax | -196K |
Effective Tax Rate | 3.9% |
Stock Price Statistics
The stock price has increased by 29.87% in the last 52 weeks. The beta is 1.68, so Sonoma Pharmaceuticals's price volatility has been higher than the market average.
Beta | 1.68 |
52-Week Price Change | 29.87% |
50-Day Moving Average | 2.66 |
200-Day Moving Average | 3.4 |
Relative Strength Index (RSI) | 72.31 |
Average Volume (20 Days) | 2.64M |
Income Statement
In the last 12 months, Sonoma Pharmaceuticals had revenue of 12.73M and earned -4.83M in profits. Earnings per share was -5.32.
Revenue | 12.73M |
Gross Profit | 4.75M |
Operating Income | -4.7M |
Net Income | -4.83M |
EBITDA | -4.53M |
EBIT | -4.7M |
Earnings Per Share (EPS) | -5.32 |
Balance Sheet
The company has 3.13M in cash and 608K in debt, giving a net cash position of 2.52M.
Cash & Cash Equivalents | 3.13M |
Total Debt | 608K |
Net Cash | 2.52M |
Retained Earnings | -194.35M |
Total Assets | 13.67M |
Working Capital | 8.68M |
Cash Flow
In the last 12 months, operating cash flow was -2.4M and capital expenditures -17K, giving a free cash flow of -2.42M.
Operating Cash Flow | -2.4M |
Capital Expenditures | -17K |
Free Cash Flow | -2.42M |
FCF Per Share | -2.66 |
Margins
Gross margin is 37.26%, with operating and profit margins of -36.91% and -37.97%.
Gross Margin | 37.26% |
Operating Margin | -36.91% |
Pretax Margin | -39.51% |
Profit Margin | -37.97% |
EBITDA Margin | -35.53% |
EBIT Margin | -36.91% |
FCF Margin | -18.96% |
Dividends & Yields
SNOA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for SNOA.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on Aug 30, 2024. It was a backward split with a ratio of 1:20.
Last Split Date | Aug 30, 2024 |
Split Type | backward |
Split Ratio | 1:20 |
Scores
Altman Z-Score | -19.05 |
Piotroski F-Score | 3 |